Encyclopedia of lung cancer /
Saved in:
| Imprint: | New York : Nova Biomedical, [2015] |
|---|---|
| Description: | 1 online resource. |
| Language: | English |
| Series: | Cancer etiology, diagnosis, and treatments Cancer etiology, diagnosis, and treatments. |
| Subject: | |
| Format: | E-Resource Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/11249302 |
Table of Contents:
- ENCYCLOPEDIA OF LUNG CANCER ; ENCYCLOPEDIA OF LUNG CANCER ; Library of Congress Cataloging-in-Publication Data; CONTENTS ; PREFACE ; Chapter 1 THERAPEUTIC ANTIBODIES IN NON-SMALL CELL LUNG CANCER: AN OVERVIEW AND FUTURE DIRECTIONS ; ABSTRACT ; INTRODUCTION ; 1. THERAPEUTIC ANTIBODIES IN CANCER: RATIONALE ; 1.1. Structure of Monoclonal Antibodies (Mab) ; 1.2. History of Therapeutic mAbs ; 1.3. Pharmacodynamic ; 1.3.1. Fab Domain ; 1.3.2. Fc Domain ; 1.3.3. Conjugated or Armed mAbs ; 1.4. Pharmacokinetics of mAbs ; 1.4.1. FcRn Receptor ; 1.4.2. Administration and Absorption
- 1.4.3. Distribution 1.4.4. Metabolism and Elimination ; 1.4.5. Engineered IgG and Their Pharmacokinetics ; 1.4.6. Other Factors Influencing the Pharmacokinetics of mAbs ; 1.5. Immunogenicity and Safety of mAbs ; 1.5.1. Anti-Antibody Response (AAR) ; 1.5.2. Cytokine Release Syndrome (CRS) ; 2. THERAPEUTIC ANTIBODIES IN NON SMALL CELL LUNG CANCER (NSCLC): PRE-CLINICAL AND CLINICAL STUDIES ; 2.1. Anti-VEGF Antibodies ; 2.1.1. Vascular Epidermal Growth Factor (VEGF) and NSCLC ; 2.1.2. Bevacizumab ; 2.1.2.1. Preclinical Studies with Bevacizumab ; 2.1.2.2. Pharmacokinetic
- 2.1.3. Clinical Trials of Bevacizumab Combined with Chemotherapy 2.1.3.1. Phase II Clinical Trial ; 2.1.3.2. Phase II Clinical Trial in Squamous Non Small Cell Lung Cancer ; 2.1.3.3. Phase III Clinical Trials in Non Squamous Non Small Cell Lung Cancer ; 2.1.3.4. Phase IV Clinical Trials in Non Squamous Non Small Cell Lung Cancer ; 2.1.3.5. Bevacizumab As Maintenance Therapy: Current Concepts ; 2.1.3.6. Bevacizumab As Maintenance Therapy: Future Directions; 2.1.4.Clinical Trials of Bevacizumab Combined with Targeted Therapy ; 2.1.4.1.Erlotinib ; 2.1.4.1.1. Phase I and II Trials
- 2.1.4.1.2. Phase III Trial 2.1.4.1.3. Erlotinib and Bevacizumab: Future Directions ; 2.1.4.2. Sunitinib ; 2.1.5. Clinical Trials of Bevacizumab in Elderly Patients ; 2.1.6. Predictive Markers ; 2.1.6.1. Current Concepts ; 2.1.6.2. Future Directions ; 2.1.7. Anti-VEGFR2: Ramucirumab ; 2.1.8. Fab Anti-VEGF: Ranibizumab ; 2.2. Anti-HER Antibodies ; 2.2.1. EGFR and Signaling Pathways ; 2.2.1.1. ERBB1 (EGFR) ; 2.2.1.2. ERBB2 (HER2) ; 2.2.2. Cetuximab: Anti-EGFR Antibody ; 2.2.2.1. Pre-Clinical Studies ; 2.2.2.2. Preclinical Studies on the Pulmonary Administered of Cetuximab
- 2.2.2.3. Pharmacokinetic 2.2.2.4. Clinical Trials of Cetuximab Combined with Chemotherapy ; 2.2.2.4.1. Phase I/II ; 2.2.2.4.1.1. First Line Therapy ; 2.2.2.4.1.2. Second Line Therapy ; 2.2.2.4.1.3. Bronchioloalveolar Carcinoma ; 2.2.2.4.2. Phase III ; 2.2.2.4.3. Cetuximab and Other Targeted Therapies ; 2.2.2.4.3.1. Anti-EGFR Tyrosine Kinase Inhibitor ; 2.2.2.4.3.2. Bortezomib ; 2.2.2.4.4. Cetuximab and Radiotherapy ; 2.2.2.4.5. Cetuximab and Predictive Markers ; 2.2.3. Anti-EGFR: Matuzumab ; 2.2.4. Anti-EGFR: Nimotuzumab ; 2.2.5. Anti-EGFR: Panitumumab; 2.2.6. Anti-EGFR: Necitumumab